EndoSound
Raising nowOperatingEndoSound, Inc.
Biotech · Portland, OR
Driving access to high-impact endoscopic ultrasound
This company has an open fundraising round.
Financials
FY2023–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Dec 31, 2024| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Series A Preferred Stockpreferred | 3,898,468 | — | 26.4% | $1.26Jun 2026 |
| Series Seed-1 Preferred Stockpreferred | 1,950,898 | — | 13.2% | — |
| Common Stock | 8,892,830 | 1 | 60.3% | — |
| Total | 14,742,196 | 100% |
Principal holders% as the filing states it, Jun 2, 2026
- Stephen Steinberg20%+of votes
Sold to the crowd
- Reg CF · Jun 2025$1.5M
- Reg CF · Jun 2026102,877 Equity at $1.26$130K· 130 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
7 people
Dr. Steinberg is a GI pioneer with 40+ years of experience, thousands of EUS procedures, and 30 years in academic medicine. A KOL and the co-inventor, he’s helped shape the future of gastrointestinal diagnostics.
A veteran biomedical engineer with 30+ years in ultrasound, 19 patents, and 3 medtech startups. Co-inventor and former engineering lead at GE, Tyco Healthcare, and Sonivate.
18-years medtech sales leader and former National Sales Director at PENTAX Medical. A proven EUS strategist with deep industry ties, he's led disruptive launches and now drives EndoSound’s commercial growth.
Operations executive with experience scaling early- and mid-stage technology companies. Began his career as an US engineer and later served in senior leadership roles including CEO and President. Helped lead MicroConnex through operation
Names and titles as disclosed on SEC Form C, WeFunder. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 1 annual reports (FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 12 filings on EDGAR- Form C/AAug 3, 20260001850978-26-000010EDGAR
- Form DJun 17, 20260001850978-26-000009EDGAR
- Form CJun 2, 20260001850978-26-000005EDGAR
- Form C-ARApr 29, 20260001850978-26-000004EDGAR
- Form C-UFeb 26, 20260001850978-26-000001EDGAR
- Form C/AOct 28, 20250001850978-25-000003EDGAR
- Form D/AAug 11, 20250001850978-25-000002EDGAR
- Form CJun 18, 20250001670254-25-000659EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.